Hayat Pharmaceutical Industries Co. PLC

ASE:HPIC Stock Report

Market Cap: د.أ23.8m

Hayat Pharmaceutical Industries Past Earnings Performance

Past criteria checks 2/6

Hayat Pharmaceutical Industries has been growing earnings at an average annual rate of 0.4%, while the Pharmaceuticals industry saw earnings growing at 11.5% annually. Revenues have been growing at an average rate of 3.5% per year. Hayat Pharmaceutical Industries's return on equity is 8.2%, and it has net margins of 14.4%.

Key information

0.4%

Earnings growth rate

0.4%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate3.5%
Return on equity8.2%
Net Margin14.4%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Hayat Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASE:HPIC Revenue, expenses and earnings (JOD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2315261
31 Mar 2317371
31 Dec 2217461
30 Sep 2216361
30 Jun 2215361
31 Mar 2214260
31 Dec 2117460
30 Sep 2118570
30 Jun 2118470
31 Mar 2117470
31 Dec 2017470
30 Sep 2017460
30 Jun 2017470
31 Mar 2017460
31 Dec 1916360
30 Sep 1915360
30 Jun 1914350
31 Mar 1914350
31 Dec 1814350
30 Sep 1813250
30 Jun 1813350
31 Dec 1713250
30 Sep 1713350
30 Jun 1712340
31 Mar 1711240
31 Dec 1611240
30 Sep 1610330
30 Jun 1611240
31 Mar 1611240
31 Dec 1511240
30 Sep 1511240
30 Jun 1511250
31 Mar 1511250
31 Dec 1411250
30 Sep 1410240
30 Jun 1410240
31 Mar 149240
31 Dec 1310240
30 Sep 1310250
30 Jun 139240
31 Mar 138240

Quality Earnings: HPIC has high quality earnings.

Growing Profit Margin: HPIC's current net profit margins (14.4%) are lower than last year (17.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: HPIC's earnings have grown by 0.4% per year over the past 5 years.

Accelerating Growth: HPIC's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: HPIC had negative earnings growth (-15.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.8%).


Return on Equity

High ROE: HPIC's Return on Equity (8.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.